Login to Your Account

Analysts mulled what the approval in the European Union (EU) of Amgen Inc.'s cholesterol drug Repatha (evolocumab) might mean for the compound's fate in the U.S., and for same-class competitor Praluent (alirocumab) from Regeneron Pharmaceuticals Inc. and Sanofi SA in both regions.
LONDON – The extent to which big pharma has piled into rare disease research is highlighted in a new study of patents in the field launched at the Biotechnology Industry Organization meeting on Monday.

Summer has been slow to arrive in Europe this year, a blessing for patients with erythropoietic protoporphyria, an extreme sensitivity to sunlight, who have been awaiting the market rollout of the first approved treatment, Scenesse.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: